Navigation Links
Rapid Generic Erosion of Branded Agents, Including Market-Leading Viagra, Will Cause Sales of Erectile Dysfunction Drugs to Remain Flat Over the Next Decade
Date:1/19/2009

However, Increases in the Drug Treated Population Will Temper Losses Incurred by Leading Agents, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the anticipated launch of five emerging drugs during the 2007-2017 forecast period, total sales for erectile dysfunction therapies will remain relatively constant, totaling $2.2 billion in 2007 and $2.1 billion in 2017. Rapid generic erosion, following patent expiries that begin in the United States in 2012 for the market leader, Pfizer's Viagra (sildenafil), will be the key event impacting the erectile dysfunction market. However, the decline in Viagra sales will be tempered by more widespread use of sildenafil overall, as greater numbers of patients are expected to seek treatment and receive prescription drug therapy for erectile dysfunction when less-expensive, generic versions of sildenafil become available.

The new Pharmacor report entitled Erectile Dysfunction finds that while therapeutic substitution of less-expensive, generic sildenafil for branded phosphodiesterase type 5 (PDE5) inhibitors will contribute to a significant loss of sales for Eli Lilly's Cialis and Bayer Healthcare/Schering-Plough/GlaxoSmithKline's Levitra, the availability of generic PDE5 inhibitors will encourage more patients to seek treatment for erectile dysfunction, driving increases in the diagnosed and drug-treated populations through 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

According to the report, opportunity remains for emerging agents that can treat patients who do not respond to treatment with available PDE5 inhibitors or for whom these agents are contraindicated. However, several second-generation PDE5 inhibitors that are forecast to launch over the next decade are not expected to generate sufficient interest among prescribing physicians to notably offset declines anticipated in the erectile dysfunction market. Reimbursement hurdles will also constrain the market as third-party payers in the United States who currently provide reimbursement for PDE5 inhibitors may remove branded PDE5 inhibitors from their formularies, further encouraging patients to adopt less expensive treatment alternatives.

"Across the major markets under study, first-line therapies for erectile dysfunction are largely regarded as lifestyle therapies and, as such, do not qualify for reimbursement under national healthcare systems," said Kathryn Benton, analyst at Decision Resources. "Although some third-party payers in the United States reimburse PDE5 inhibitors as tier-two or tier-three drugs, steep copayments and, in some instances, prior authorization requirements and quantity limits discourage many patients from taking these drugs."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Allergy Sufferers to Benefit from New, Improved Rapid Relief Medication This Spring
2. First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center
3. Belmont(R) Rapid Infuser Helps Save Officers Life
4. Rapid Response Teams Dont Cut Hospital Heart Attacks, Death Rates
5. Ultrasound waves aid in rapid treatment of DVT
6. Frutarom Continues to Implement its Rapid Growth Strategy
7. New Research Shows MicroPhage Test Accurately and Rapidly Detects Serious Bacterial Infections
8. Lees Pharmaceutical Kept Up the Rapid Pace of Growth; Profit Attributable to Shareholders Surged 176% in the Nine Months of 2008
9. Central California Doctors Now Using Fast RapidArc(TM) Radiotherapy Technology to Battle Cancer
10. Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments
11. Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: